Eli Lilly's Mounjaro and Zepbound are fueling triple-digit year-over-year GLP-1 revenue growth and expanding US market share, driven by their accelerated weight loss rates and increased manufacturing capacity. Despite elevated R&D expenses, LLY shares are deemed undervalued at a 3Y PEG ratio of 0.91x, with the stock exhibiting a bullish breakout from a prior downtrend. However, the company faces potential future growth headwinds from Novo Nordisk's upcoming oral obesity/diabetes candidates.
Eli Lilly (LLY) is demonstrating robust performance, driven by its GLP-1 drugs Mounjaro and Zepbound, which exhibit accelerated weight loss rates compared to Novo Nordisk's Wegovy. This has fueled triple-digit year-over-year GLP-1 revenue growth and expanding US incretin analogs market share, despite facing CVS headwinds. Increased manufacturing capacity has been a key enabler for this market expansion. Despite elevated IPR&D expenses, LLY maintains profitable growth trends, leading to an estimated 3Y PEG non-GAAP ratio of 0.91x, suggesting the stock is currently undervalued. The stock has broken out from a prior downtrend since early 2024, indicating growing bullish support and a potential trading floor emerging by August 2025. While LLY's current trajectory is strong, investors should monitor upcoming oral obesity/diabetes candidates from Novo Nordisk (NVO). NVO's robust weight loss rates in these new candidates could potentially introduce growth headwinds for LLY, intensifying future market competition in the GLP-1 space.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment
